Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease

Completed · Phase 2

Conditions studied: Graft-Versus-Host Disease

In brief

This study will evaluate the response rate to treatment with pentostatin in steroid-refractory acute graft versus host disease.

Key facts

Study ID

NCT00201786

Run by

Ohio State University Comprehensive Cancer Center

People needed

8

Starts

2003-07-01

Expected to finish

2013-07-01

Last updated by the study team

2016-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have biopsy proven grade II-IV acute GVHD refractory to systemic corticosteroids
• No chronic GVHD
• Age ≥ 18 years
• Evidence of myeloid engraftment (ANC ≥ 0.5 x 109/l)
• Performance status 0-3

You may not qualify if…

• Patients on mechanical ventilation or who have resting O2 saturation <90% by pulse-oximetry.
• Patients on renal dialysis or who have an estimated creatinine clearance of < 30 ml/min/1.73 m2.
• Patients with documented clinical infection (progressive symptoms despite antibiotics or continued fever) cannot be enrolled on study until infection is controlled.

Where it is running

• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.